EDITOR'S DESK

Eying Up The Era Of Topical Biologics

Claris Bio’s phase 1/2 clinical trial in patients with Stage 2 or 3 Neurotrophic Keratitis (NK) is breaking new ground in the development of topically administered biologic therapies. 

Doubling Down On Biopharma's Growing Skills Drought

The biopharmaceutical industry is building manufacturing capacity at breakneck speed. According to PhRMA, there are 1,580-and-counting biopharma manufacturing facilities in the U.S. alone. Problem is, we're way short on filling those facilities with skilled labor. NIIMBL wants to change that. Here's how, and a great opportunity for big pharma, biotech sponsors, CDMOs, academics, and more to help.

Debra Weiss, RN: Big Impact In Small, Non-Profit Bio

The career of Debra Weiss, RN, MSN, and COO at the biopharma Gates Medical Research Institute (Gates MRI), offers a case study in creating success through service-oriented leadership.

The Industry's Positive Outlook For ADCs In 2024

Check out the results of DeciBio's Antibody-Drug Conjugates 2024 Industry Survey, which predict another bullish year for the growing modality.

GUEST COLUMNISTS

BIOPROCESSING WHITE PAPERS

  • How To Make The Best LNPs

    There are various factors that require careful consideration throughout the process of formulating LNPs and utilizing them for successful mRNA delivery and translation.

BIOPROCESS ONLINE CONTENT COLLECTIONS

23_10_BPO_MilliporeSigma_VaccineEbook_300x200

 

This collection of articles, produced through a partnership between MilliporeSigma and Bioprocess Online, highlights the need for ongoing investment in resilient biomanufacturing capacity and supply chains to ensure the reliable delivery of health technologies like vaccines, even during crisis conditions.

More Content Collections